{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:30Z","timestamp":1790659650258,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111435","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T13:08:44Z","timestamp":1703596124000},"page":"111435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment"],"prefix":"10.1016","volume":"127","author":[{"given":"Amirhossein","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yekta","family":"Ghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2023.111435_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization \u2013 systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"17","key":"10.1016\/j.intimp.2023.111435_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179716","article-title":"Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations","volume":"23","author":"Swierczewska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.111435_b0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/CCID.S402453","article-title":"Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature","volume":"16","author":"Alotaibi","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"10.1016\/j.intimp.2023.111435_b0020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa","volume":"183","author":"Ingram","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.111435_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/exd.14633","article-title":"Which hidradenitis suppurativa comorbidities should I take into account?","volume":"31","author":"Tzellos","year":"2022","journal-title":"Exp. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.111435_b0030","doi-asserted-by":"crossref","first-page":"e1576","DOI":"10.1002\/hsr2.1576","article-title":"Association between metabolic syndrome and prevalent skin diseases: A systematic review and meta-analysis of case-control studies","volume":"6","author":"Sodagar","year":"2023","journal-title":"Health Science Reports"},{"issue":"8","key":"10.1016\/j.intimp.2023.111435_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082094","article-title":"Hidradenitis Suppurativa: Where We Are and Where We Are Going","volume":"10","author":"Scala","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.intimp.2023.111435_b0040","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/jdv.19286","article-title":"Hidradenitis suppurativa presents a methylome dysregulation capable to explain the pro-inflammatory microenvironment: Are these DNA methylations potential therapeutic targets?","volume":"37","author":"Radhakrishna","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111435_b0045","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.16147","article-title":"Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa","volume":"34","author":"Zouboulis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.intimp.2023.111435_b0050","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa?-15 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp. Dermatol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.111435_b0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/exd.14123","article-title":"Endpoints of clinical trials for Hidradenitis Suppurativa: proceedings of a round-table session","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2023.111435_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","author":"Jepsen","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111435_b0065","article-title":"Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature","volume":"59","author":"Martora","year":"2023","journal-title":"Medicina (kaunas)"},{"issue":"12","key":"10.1016\/j.intimp.2023.111435_b0070","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1097\/DSS.0000000000003235","article-title":"Improvement in quality of life and pain in patients with hidradenitis suppurativa after wide local excision: A prospective study","volume":"47","author":"Dick","year":"2021","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.intimp.2023.111435_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2023.111435_b0080","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.111435_b0085","doi-asserted-by":"crossref","first-page":"T772","DOI":"10.1016\/j.ad.2023.08.001","article-title":"Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future","volume":"114","author":"Mansilla-Polo","year":"2023","journal-title":"Actas Dermosifiliogr."},{"issue":"4","key":"10.1016\/j.intimp.2023.111435_b0090","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"89","author":"Jepsen","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.111435_b0095","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.111435_b0100","unstructured":"L. National Heart, and Blood Institute, Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group, 2014."},{"key":"10.1016\/j.intimp.2023.111435_b0105","unstructured":"L. National Heart, and Blood Institute, Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, 2014."},{"key":"10.1016\/j.intimp.2023.111435_b0110","unstructured":"L. National Heart, and Blood Institute, Quality Assessment of Clinical trials, 2014."},{"issue":"2","key":"10.1016\/j.intimp.2023.111435_b0115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.intimp.2023.111435_b0120","series-title":"Upadacitinib, StatPearls, StatPearls Publishing Copyright \u00a9 2023","author":"Padda","year":"2023"},{"issue":"3","key":"10.1016\/j.intimp.2023.111435_b0125","doi-asserted-by":"crossref","first-page":"AB42","DOI":"10.1016\/j.jaad.2023.07.172","article-title":"43799 Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Study","volume":"89","author":"Kimball","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.111435_b0130","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.111435_b0135","first-page":"114","article-title":"Refractory, severe hidradenitis suppurativa Hurley stage III shows positive response to a therapy with the combination of brodalumab (Il-17-receptor-inhibitor) and Upadacitinib (JAK - inhibitor). A Case Report","volume":"31","author":"Gewiss","year":"2022"},{"key":"10.1016\/j.intimp.2023.111435_b0140","article-title":"Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa","author":"Abu Rached","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111435_b0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"issue":"8","key":"10.1016\/j.intimp.2023.111435_b0150","doi-asserted-by":"crossref","first-page":"B16","DOI":"10.1016\/j.jid.2022.05.962","article-title":"LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome","volume":"142","author":"Dunnick","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.111435_b0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients","volume":"6","author":"Savage","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.intimp.2023.111435_b0160","doi-asserted-by":"crossref","first-page":"omad003","DOI":"10.1093\/omcr\/omad003","article-title":"Successful treatment of Hidradenitis Suppurativa with tofacitinib: two cases and a review of the literature","volume":"2023","author":"Sadeghzadeh Bazargan","year":"2023","journal-title":"Oxf. Med. Case Reports"},{"issue":"7","key":"10.1016\/j.intimp.2023.111435_b0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: A Review in Rheumatoid Arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.intimp.2023.111435_b0170","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10875-023-01454-2","article-title":"Rheumatology Research, STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib","volume":"43","author":"Olbrich","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2023.111435_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model","volume":"9","author":"Vossen","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111435_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.intimp.2023.111435_b0185","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"issue":"508","key":"10.1016\/j.intimp.2023.111435_b0190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.intimp.2023.111435_b0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/exd.14092","article-title":"Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets?","volume":"29","author":"Frew","year":"2020","journal-title":"Exp. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.111435_b0200","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jid.2019.08.453","article-title":"Enrichment of Plasma Cells in the Peripheral Blood and Skin of Patients with Hidradenitis Suppurativa","volume":"140","author":"Musilova","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.111435_b0205","article-title":"Mast cells are upregulated in Hidradenitis Suppurativa Tissue, associated with epithelialized tunnels and normalised by Spleen Tyrosine Kinase Antagonism","author":"Flora","year":"2023","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.intimp.2023.111435_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100001","article-title":"Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions","volume":"1","author":"Jiang","year":"2021","journal-title":"JID Innovations"},{"issue":"10","key":"10.1016\/j.intimp.2023.111435_b0215","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jid.2019.10.025","article-title":"Low Prevalence of <em>GSC<\/em> Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa","volume":"140","author":"Duchatelet","year":"2020","journal-title":"J, Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111435_b0220","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdin.2020.05.005","article-title":"Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD International"},{"issue":"4","key":"10.1016\/j.intimp.2023.111435_b0225","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jid.2022.08.056","article-title":"Cytochrome P450 Genes Mediated by DNA Methylation Are Involved in the Resistance to Hidradenitis Suppurativa","volume":"143","author":"Radhakrishna","year":"2023","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111435_b0230","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/bjd\/ljac096","article-title":"Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies","volume":"188","author":"Schell","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111435_b0235","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2023.111435_b0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111435_b0245","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (heidelb)"},{"issue":"4","key":"10.1016\/j.intimp.2023.111435_b0250","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111435_b0255","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2023.111435_b0260","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40267-018-0551-x","article-title":"Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA","volume":"34","author":"McKeage","year":"2018","journal-title":"Drugs Ther Perspect"},{"issue":"11","key":"10.1016\/j.intimp.2023.111435_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282763","article-title":"Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo","volume":"18","author":"Flora","year":"2023","journal-title":"Plos one"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923017629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923017629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:11:08Z","timestamp":1761588668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923017629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":53,"alternative-id":["S1567576923017629"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111435","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111435"}}